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1. Introduction
There are well-established examples of highly penetrant mutations in genes that are directly
involved in carcinogenesis and result in a high risk of cancer in the individuals who carry these
mutations. Some of the best examples include syndromes of defective DNA repair, such as
xeroderma pigmentosum [1]. However, these examples tend to be very rare and thus contrib‐
ute minimally to the overall burden of cancer risk. Nevertheless, it has long been suspected
that less penetrant susceptibility may be produced by much more common variants in the
same cancer-related genes, for example, in the form of single nucleotide polymorphisms
(SNPs), that presumably would be less disruptive and therefore produce more subtle effects
on the function of the encoded proteins but which could contribute greatly to overall cancer
attributable risk in populations due to their widespread occurrence [1]. Because several of these
common polymorphisms occur in DNA repair proteins, many epidemiologic studies have
examined their relationship to cancer risk [2-4].
These studies have looked at all different types of cancer, many different at-risk populations,
several different DNA repair pathways, and a variety of polymorphisms at different sites
[5-18]. The results to date at best have been inconsistent, conflicting and confusing with many
examples of positive, negative or null associations between particular polymorphisms and
particular cancers, even in multiple large meta-analyses of the data. For example, a very recent
large, rigorous and systematic review of the literature on the involvement of DNA repair
polymorphisms in human cancer reached the conclusion that because of the inconsistencies in
the literature “none of the cancer genome-wide association studies (GWAs) published so far
showed highly statistically significant associations for any of the common DNA repair gene
variants” and “clarification of the discrepancies in the literature is needed.” [4] It was suggested
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that one way to proceed would be that “gene/environment and gene/lifestyle interactions for
carcinogenic mechanisms involving DNA repair should be investigated more systematically
and with less classification error.” [4] However, even in studies of populations with exposures
to known environmental carcinogens and the cancers most closely associated with those
exposures, the results of DNA repair polymorphism studies have not always been clear-cut;
these inconsistencies may also be the result of poor exposure classification, multiple con‐
founders and/or poor understanding of the exact mechanisms of DNA damage and/or repair
[19-23]. In other words, what is needed is to study model systems where there are clear linkages
between the exposure to the carcinogenic risk factor and the specific DNA damage that it
produces with the DNA repair mechanisms that would correct those particular defects.
In  environmental  carcinogenesis  studies  of  DNA repair  polymorphisms,  the  majority  of
the work has focused on base excision repair  (BER) or nucleotide excision repair  (NER)
pathways,  since these are thought to play dominant roles in the repair of  damage from
exogenous  carcinogens,  including  chemical  carcinogens.  In  both  of  these  pathways,  nu‐
merous polymorphisms in numerous proteins  that  make up the DNA repair  machinery
have been examined. However, much of the focus has been on the particular proteins in
the respective pathways that contain the most common polymorphic variants, in particu‐
lar the x-ray cross complementing-1 (XRCC1) protein in BER and the xeroderma pigmen‐
tosum-D (XPD) protein in NER [24-38].
This is also understandable because of the critical roles that each of these proteins play in their
respective pathways. For example, in BER the particular type of damage produced by exposure
to a chemical carcinogen is usually recognized and removed by a specific DNA glycoslase. The
BER apparatus includes numerous other proteins that complete the repair at the resultant
abasic site once the damage is removed: apurinic/apyrimidinic endonuclease (APE1),
poly(ADP-ribose) polymerase-1 (PARP-1), poly(ADP-ribose) polymerase-2 (PARP-2), DNA
polymerase β (Pol β) and DNA ligase IIIα (Lig III). AP endonuclease is responsible for cleaving
the phosphodiester bond at the abasic site created by the glycosylase. PARP-1 and to a lesser
extent PARP-2 participate in the repair process by catalyzing ribosylation of a number of DNA-
bound proteins, thereby decreasing the affinity of these proteins for DNA, and allowing the
repair machinery to access the damaged site. Pol β, the polymerase involved in short patch
repair, provides two essential activities, deoxyribophosphodiesterase activity which releases
the 5' sugar phosphate group, and gap filling synthesis, where one nucleotide is added to the
3' OH. Finally, Lig III seals the nick in an ATP-dependent manner [39, 40]. The XRCC1 protein
is critical to this process since it acts as a scaffold protein in this pathway and appears to
enhance the activity of the other BER proteins. Although XRCC1 has not been demonstrated
to contain enzymatic activity of its own, it is thus necessary for coordinating and regulating
the early and late stages of BER through its protein interaction modules [41, 42].
XRCC1 is known to contain three common polymorphic sites that might be expected to have
an effect on XRCC1 structure and function because they occur in or near important protein
domains [11]. For example, the polymorphism at amino acid residue 194, which results in the
substitution of a tryptophan for the normal arginine, occurs in the XRCC1 N-terminal domain
from amino acid residues 1-195 that has been observed to mediate its interaction with the palm-
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thumb domain of Pol β [43]. A second polymorphism at amino acid residue 280, which results
in the substitution of a histidine for the normal arginine, occurs in the region between the N-
terminal domain and the BRCA1 carboxy terminal (BRCT1) domain of the protein and close
to the nuclear localization signal site and thus could affect the relationship between these two
critical domains and/or the protein’s localization ability [44]. The third and most common
polymorphism in XRCC1 occurs at amino acid residue 399, resulting in the substitution of a
glutamine for the normal arginine, within the highly conserved BRCT1 domain from amino
acid residues 315-403, which has been associated with the functioning of PARP1, PARP2 and
APE1 [45].
Like BER, NER occurs in a series of steps: damage recognition, unwinding and demarcation
of the DNA, excision of the single-stranded fragment containing the damaged site, and DNA
re-synthesis. NER is accomplished primarily through the action of proteins of the xeroderma
pigmentosum family of genes which are categorized into 7 different groups (A-G). XPC and
XPE proteins are involved in recognition of different types of DNA damage. XPB and XPD are
DNA helicases that function as subunits of the transcription factor IIH complex (TFIIH) to
promote DNA bubble formation at the damaged site by unwinding the DNA as XPA com‐
plexes with replication protein A (RPA) for demarcation. XPF and XPG are structure-specific
endonucleases for excision of the damaged site. Finally, replicative DNA polymerase and DNA
ligase I complete the repair [46, 47]. XPD is one of the major players in NER and is essential
for life [48, 49].
XPD is also known to contain at least two common polymorphic sites, namely at amino acid
residues 312 (aspartic acid->asparagine) and 751 (lysine->glutamine) [50]. The 751 site is
assumed to be particularly important for XPD function since it occurs in the C-terminal domain
of the protein which has been suggested to interact with the p44 helicase activator protein of
the TFIIH complex [51]; also, it is been shown that an XPD mutation that results in the loss of
the final 17 C-terminal amino acids, including residue 751, results in the clinical disease
phenotype of trichothiodystrophy [52].
In summary, an ideal system for investigating the role of DNA repair polymorphisms in
carcinogenesis might be an exposure to a known chemical carcinogen that produces specific
types of DNA damage that are repaired by the BER and/or NER pathways where the effects
of common polymorphisms in XRCC1 and XPD on the damage and repair could be studied.
2. A model for the study of the epidemiology of dna repair polymorphisms
in carcinogenesis
Such a potential model system for the study of the role of DNA repair polymorphisms in
chemical carcinogenesis is provided by the known carcinogen vinyl chloride (VC) because
considerable detail is available concerning the molecular biology of its pathogenic pathway
which allows for careful study of the role of DNA damage and repair in the carcinogenic
process in exposed human populations through the application of molecular epidemiologic
approaches (Figure 1).
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As noted, VC is a well-established animal and human carcinogen. It is most strongly associated
with liver cancer, in particular the rare, sentinel neoplasm of angiosarcoma of the liver (ASL),
a malignant tumor of the endothelial cells of the liver [53]. However, VC has also been
identified as a cause of hepatocellular carcinoma (HCC), the corresponding malignant tumor
of the parenchymal cells of the liver [54]. In addition, it has been associated with other
malignancies, e.g., lung and brain, although these associations remain much more controver‐
sial. The most significant exposures to VC occur in the petrochemical and plastics industries
because VC is used in the manufacture of polyvinyl chloride, one of most high-volume plastics
in the world. For example, it is estimated that worldwide more than 2,200,000 workers are
probably occupationally exposed to VC. General population exposures also occur primarily
through the air and water. For example, elevated levels of VC have been found not only in the
air near VC manufacturing and processing facilities but also in the vicinity of many hazardous
waste sites and municipal landfills, either due to the direct disposal of VC or from the microbial
degradation of other chlorinated solvents to form VC. In some cases, dangerously high levels
have been detected in the air at some of these landfills [53]. General population exposures may
also occur from tobacco smoke, drinking water from PVC pipe, and consumption of food and
beverages from PVC packaging and bottles, although probably at much lower levels.
VC is a gas so the most significant exposures are respiratory. Following inhalation, absorption
is rapid in humans and most subsequent metabolism occurs in the liver [53]. Phase I metabo‐
lism is primarily via the cytochrome P-450 isoenzyme 2E1 (CYP2E1) to generate the reactive
intermediates chloroethylene oxide (CEO) and chloracetaldehyde (CAA) which are further
metabolized in phase II reactions by glutathione-S-transferases (GSTs) and aldehyde dehy‐
drogenase 2 (ALDH2) to end products for ultimate excretion. However, CEO and CAA can
readily interact with cellular macromolecules, including DNA, to produce promutagenic
effects. VC biotransformation to CEO probably occurs principally in hepatocytes, but the
epoxide can also reach and react with adjacent sinusoidal lining cells, so that mutagenic effects
can occur in parenchymal liver cells and non-parenchymal endothelial cells, providing a
logical rationale for the association between VC exposure and ASL as well as HCC [55]. The
major VC-associated liver DNA adduct is 7-(2-oxoethyl)guanine, comprising up to 98% of all
adducts formed. However, this adduct is eliminated from the DNA with a very short half-life,
principally by chemical depurination, and is not considered to be promutagenic. On the other
hand, three etheno DNA adducts are also formed in much less abundance, but they are known
to be promutagenic. These are: N2,3-ethenoguanine (εG) ; 1,N6-ethenoadenine (εA) ; and 3,N4-
ethenocytosine (εC) [56].
The promutagenic properties of etheno-DNA adducts that are not fully repaired by one or
another of the DNA repair pathways have been well documented in experimental systems in
vitro, as well as in vivo in bacterial and mammalian cells. The εA adduct generates A->T, A->G
and A->C base changes; the εG adduct generates G->A base changes; and the εC adduct
generates C->A and C->T base changes [55]. These experimental results are consistent with the
tumor mutational spectra identified in exposed animals and humans in oncogenes and tumor
suppressor genes. Of particular interest have been the A->T transversions at codons 179, 249
and 255 of the TP53 tumor suppressor gene generated by εA adducts and the G->A transitions
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at codon 13 of the K-ras oncogene generated by εG adducts, because of their frequent occur‐
rence in human ASLs from VC-exposed individuals but not in sporadic ASLs in individuals
without VC exposure. In addition, other results suggest that these VC-associated mutations,
particularly the codon 13 K-ras mutation, may be a relatively early event in VC carcinogenesis,
and thus the occurrence of these mutations may be useful biomarkers of cancer risk in exposed
individuals, as discussed below.
Figure 1. Proposed mechanism of VC-induced DNA damage and repair as a model system for the study of the effects
of polymorphisms in BER and NER pathways.
The G->A transition at codon 13 of K-ras results in the substitution of an aspartic acid for the
normal glycine at amino acid residue 13 in the encoded p21 protein product. This substitution
is believed to be oncogenic, having been identified in other human tumors as well. The
oncogenic mechanism of action of this substitution is thought to be through the production of
a conformational change in p21 which may be responsible for altering its intrinsic GTPase
activity, thus affecting signal transduction within the cell leading to uncontrolled growth and
division [57]. Similarly, the A->T transversions at various codons of p53 produce their corre‐
sponding amino acid substitutions in the encoded p53 protein product, all changes that have
been shown to cause the protein to adopt its so-called “malignant” conformation with a
concomitant loss of its normal tumor suppressor activity [57]. These protein changes provide
a useful indicator of the pathogenic consequences of the occurrence of the corresponding
mutations, as well as convenient intermediate biomarkers of VC effect to study the molecular
epidemiology of VC carcinogenesis in exposed human populations, including the effects of
polymorphisms in the relevant DNA repair pathways.
The Molecular Epidemiology of DNA Repair Polymorphisms in Carcinogenesis
http://dx.doi.org/10.5772/53936
583
It has been shown that the mutant ras-p21 protein containing aspartic acid for glycine at
amino acid residue 13 can be distinguished from the wild-type protein and other mutant
ras-p21  proteins  immunologically  with  a  mouse  monoclonal  antibody  specific  for  this
protein.  For  cells  in  culture  that  contain  the  mutant  ras  gene,  it  is  possible  to  use  this
monoclonal  antibody  to  detect  mutant  ras-p21  expression  in  the  cells  by  immunocyto‐
chemistry  and  in  the  extracellular  supernatant  by  immunoblotting.  In  analogous  situa‐
tions  in  vivo,  mutant  Asp  13  ras-p21  can  be  detected  in  tumor  tissue  by
immunohistochemistry  and  in  the  serum  by  immunoblotting  of  VC-exposed  workers
with  ASLs known to  contain  the  mutant  ras  gene  but  not  in  the  serum of  VC-exposed
workers with ASLs that do not contain the mutation or in unexposed controls [57-59].
An analogous, although slightly more complicated situation occurs with p53. As noted, all of
the VC-induced mutations in the p53 gene have been shown to cause a similar conformational
change in the encoded p53 protein that results in the exposure of a common epitope, which is
normally not immunologically detectable in the wild-type protein. Thus, these mutant p53
proteins can be distinguished from wild-type p53 immunologically with a mouse monoclonal
antibody that binds to this mutant-specific epitope. For cells in culture that contain the mutant
p53 genes, it is possible to use this monoclonal antibody to detect mutant p53 protein expres‐
sion in the cells by immunocytochemistry and in the extracellular supernatant by immuno‐
blotting or by enzyme-linked immunosorbent assay (ELISA). In the analogous situation in
vivo, mutant p53 can be detected in the tumor tissue by immunohistochemistry and in the
serum by immunoblotting or ELISA of VC-exposed workers with ASLs known to contain the
mutant p53 genes but not of VC-exposed workers with ASLs that do not contain the mutations
or in unexposed controls. In some cases of mutant p53-positive tumors, it is known that
individuals can also develop an antibody response to the mutant p53 which can obscure the
detection of the mutant p53 protein itself. However, it is also possible to detect these auto-
antibodies to mutant p53 using an ELISA. Thus, the detection in serum of mutant p53 protein
and/or an antibody response to mutant p53 protein can be used together to best identify
individuals who have a p53 mutation in their tumors [57, 60, 61].
Based on the above evidence, it seems that these serum biomarkers for mutant ras-p21 and
mutant p53 accurately reflect the occurrence of the corresponding DNA damage in the target
tissue of VC-exposed workers. In addition, these biomarkers have been identified not only in
VC-exposed workers with ASLs but also in VC-exposed workers with non-malignant (but
potentially pre-malignant) angiomatous lesions and in VC-exposed workers without any
apparent neoplastic disease [57, 62-64]. In a large cohort of French VC workers, the presence
of these biomarkers was found to occur with a highly statistically significant dose-response
relationship with regard to estimated, cumulative VC exposure, supporting the claim that the
generation of the biomarkers was indeed the result of the exposure [65]. Similar results with
these biomarkers have been noted in several other VC workers cohorts around the world
[66-71]. To date in these various studies, at least five VC-exposed biomarker-positive workers
without ASL have developed subsequent liver lesions presumed to be ASLs, also suggesting
that these biomarkers may have predictive value for the subsequent occurrence of cancer.
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However, at any given level of VC exposure, some workers will have none, one or both mutant
biomarkers. One possible explanation for this inter-individual variability is genetic differences
in the proteins that metabolize VC or repair the DNA damage it produces. Although poly‐
morphisms in the proteins involved in metabolizing VC have been shown to have an effect,
polymorphisms in DNA repair proteins have been found to be even more significant.
There are several potential mechanisms by which VC-induced adducts could be repaired
before they have a chance to cause mutations. As noted above, the oxoethyl adduct is removed
rapidly by chemical depurination. The potential repair of the etheno adducts, however, is more
complicated and involves the BER and NER pathways.
For example, the 1,N6-εA adducts are recognized and removed by 3-methyl adenine DNA
glycosylase which is part of the BER pathway [55]. Likewise, the 3,N4-ethenocytosine adducts
are also repaired with high efficiency by BER via the thymine DNA glycosylase. Therefore,
polymorphisms in the BER pathway that could decrease DNA repair efficiency, particularly
the polymorphisms in XRCC1, might be expected to result in an increase in εA and εC adduct
levels at any given level of exposure in VC-exposed individuals with a resultant increase in
the VC-associated mutant biomarkers, particularly the mutant p53 biomarker. In contrast, the
N2,3-ethenoguanine adducts have been shown to be not very efficiently repaired by BER [56,
72]. Thus, if they are repaired, it is likely to be by a different DNA repair pathway such as NER.
Therefore, polymorphisms in the NER pathway that could decrease DNA repair efficiency,
particularly the polymorphisms in XPD, might be expected to result in an increase in εG adduct
levels at any given level of exposure in VC-exposed individuals with a resultant increase in
the VC-associated mutant biomarkers, particularly the mutant ras-p21 biomarker.
In fact in the aforementioned French VC worker cohort, we have been able to identify the effect
of the XRCC1 polymorphisms on the occurrence of the mutant p53 biomarker, but not the
mutant ras-p21 biomarker [73-75]. The difference in effect on the two biomarkers is expected,
since, as noted the εA adducts that result in the mutant p53 biomarker are repaired efficiently
by BER but the εG adducts that result in the mutant ras–p21 biomarker are not, so changes in
XRCC1 might affect the former but should not affect the latter. Among the three XRCC1
polymorphisms, the most significant effect on the mutant p53 biomarker was attributable to
the residue 399 polymorphism. In this case, individuals who were homozygous variant Gln-
Gln at 399 had a statistically significant 1.9-fold risk of occurrence of the mutant p53 biomarker
compared to homozygous Arg-Arg wild-type individuals, even after controlling for potential
confounders including cumulative VC exposure, and the gene-environment interaction
between the polymorphism and VC exposure appeared to be potentially supra-multiplicative
[75]. Studies in other VC worker populations have found similar effects of the XRCC1 poly‐
morphisms, particularly the 399 polymorphism, on the mutant p53 biomarker, as well as other
biomarkers of DNA damage [76-79].
This is also consistent with various experimental results examining this model system. For
example, molecular modeling of the BRCT1 domains of the normal and polymorphic forms of
XRCC1 demonstrates that the 399 substitution produces significant conformational changes
in this domain, including the loss of secondary structural features such as α-helices that can
be critical for mediating protein-protein interactions that would allow XRCC1 to coordinate
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BER [80]. Also, studies of lymphoblasts from individuals of different genotypes exposed in
vitro to the reactive metabolites of VC showed that cells with the XRCC1 399 homozygous
variant Gln-Gln genotype had an approximate 4-fold decrease in efficiency of repair of εA
DNA adducts compared to cells with the homozygous wild-type Arg-Arg genotype [74, 81],
resulting in an approximate 1.8-fold increase in mutation frequency in the polymorphic cells
compared to the wild-type cells as determined by the hypoxanthine-guanine phosphoribo‐
syltransferase (HPRT) assay [82]. Based on mutational spectrum studies in CAA-exposed
human cell lines [83], the resultant increase in ฀ A DNA adducts would especially result in
an increase in A->T transversions consistent with those found in the tumors of VC-exposed
workers, as noted above.
Furthermore, in the French VC worker cohort, we have been able to identify the effect of the
XPD polymorphisms on the occurrence of both mutant biomarkers, although the most marked
and statistically significant effect was on the mutant ras-p21 biomarker, as expected [75]. In
this case, individuals who were homozygous variant at either residue 312 or 751 had a
statistically significant 2.6-3.0-fold increased risk of occurrence of the mutant ras–p21 bio‐
marker compared to homozygous wild-type individuals, even after controlling for potential
confounders including cumulative VC exposure. Furthermore, in the case of the residue 751
polymorphism, the gene-environment interaction between the polymorphism and VC
exposure, as well as the gene-gene interaction between the XPD and CYP2E1 polymorphisms
(which could increase VC metabolism to its promutagenic reactive metabolites and thus also
increase etheno-DNA adducts at any given level of VC exposure with a resultant increase in
the mutant biomarkers) appeared to be potentially multiplicative [75]. Once again, studies in
other VC worker populations have found similar effects of the XPD polymorphisms on other
biomarkers of DNA damage [77].
This is also consistent with various experimental results in this model system. For example,
molecular modeling of the normal and polymorphic forms of XPD demonstrates that these
substitutions produce discrete local conformational changes in the protein which affect its
overall structure and could affect its function [82, 84], and, in particular, are projected to
interfere with its protein-protein interactions and binding to other components of the TFIIH
complex (Figure 2; adapted from Gibbons et al. [85]). Also, studies of lymphoblasts from
individuals of different genotypes exposed in vitro to the reactive metabolites of VC showed
that cells with the XPD 751 homozygous variant Gln-Gln genotype had an approximate 5-fold
decrease in efficiency of repair of εG DNA adducts compared to cells with the homozygous
wild-type Lys-Lys genotype [82], resulting in an approximate 4.8-fold increase in mutation
frequency in the polymorphic cells compared to the wild-type cells as determined by the HPRT
assay, even though there is no difference in the level of expression of the XPD protein among
cells that are homozygous wild-type, heterozygous or homozygous polymorphic at this codon
(Figure 3). Once again, based on mutational spectrum studies in CAA-exposed human cell
lines [83], the resultant increase in ฀ G DNA adducts would especially result in an increase
in G->A transitions consistent with those found in the tumors of VC-exposed workers.
A thorough understanding of the molecular biology and molecular epidemiology of VC
carcinogenesis can provide the basis for new molecular approaches to the prevention of VC-
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induced cancers and potentially other cancers related to DNA-damaging agents. For example,
one approach to secondary prevention could be based on “personalized prevention” derived
from knowledge of the status of individual’s DNA repair capability. Although little is currently
known about methods for altering DNA repair activity, there is some evidence to suggest
augmenting DNA repair may be possible. Several in vitro studies have shown that DNA repair
processes can be increased by selenium-based compounds in response to radiation or chemi‐
cally induced DNA damage [86]. More recently, a study in mice has suggested that seleno‐
cystine administration, although it did not protect against immediate DNA damage following
ionizing radiation exposure, was nevertheless protective because it enhanced the rate of repair
of the induced DNA damage [87]. In cohorts exposed to DNA damaging agents, determination
of the dose of selenium compounds to provide an optimum effect on DNA repair could be
based on the genetic status of the exposed individuals in terms of the presence of polymor‐
phisms in key components of the repair apparatus, and the success of such interventions could
be effectively monitored by following mutant biomarkers of DNA damage.
Figure 2. Protein backbone structures showing the proposed interaction effect of XPD (blue), cyclin H (pink) and cdk7
(green) in the TFIIH complex.
3. Conclusion
VC  provides  an  instructive  model  for  the  study  of  the  role  of  DNA  repair  polymor‐
phisms in chemical carcinogenesis. A detailed understanding of the molecular biology of
VC  carcinogenesis  has  provided  new  ways  of  studying  the  molecular  epidemiology  of
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VC carcinogenesis in exposed humans, which in turn may provide the basis for new ap‐
proaches  to  the  prevention  and  treatment  of  VC-related  cancer.  This  model  could  also
have much broader implications, since other potential carcinogenic exposures share some
of the same molecular biologic pathways of damage and repair as VC similar molecular
epidemiologic biomarkers could be useful  for monitoring their  carcinogenic process and
the effect of altered susceptibility due to changes in DNA repair capability. Such studies
in additional model systems would further help to define the exact significance of DNA
repair polymorphisms in the development of human cancers.
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